GSK962040 (25 mg tablet)
Sponsors
GlaxoSmithKline
Conditions
Gastroparesis
Phase 2
Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
CompletedNCT01262898
Start: 2011-05-03End: 2013-02-26Updated: 2021-07-15
A Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric Emptying
CompletedNCT01602549
Start: 2012-07-31End: 2014-05-31Updated: 2017-02-06